Histamine H receptor: an emerging target for cancer therapy?

Achieving better clinical outcomes in cancer research requires a deeper understanding of tumoral biology and the application of this knowledge within a clinic setting. The aim of this review is to briefly summarize the current knowledge on HR molecular pharmacology, the clinical use of HR antagonists, and the most recent findings reporting HR role in cancer biology. We will discuss in detail the current landscape and clinical perspectives of the modulation of this HR on cancer progression and treatment. We propose HR as a promising molecular target for cancer drug repurposing and development.